The EAS Advanced Course in Clinical Excellence in Cardiovascular Prevention and Lipidology has received accrediation by the European Board for Accreditation in Cardiology (EBAC) for 12 hours of External CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS Advanced Course in
Clinical excellence in cardiovascular prevention and lipidology

Paris, France, February 9-10, 2012

Delegates should arrive in the evening of February 8, 2012.

Programme February 9, 2012

08:30

Welcome, Course Objectives, presentation of participants
Eric Bruckert and Olov Wiklund

09:00-10:00

Lecture: Petri Kovanen

Atherosclerotic plaque: update on the pathophysiology: role of LDL

Objective: update on the key steps in the development of the atherosclerotic plaque
Discussion: 15 mins
10:00-11:00

Lecture: John Chapman

Update on HDL biology: structure, metabolism and function in health and disease

Objective: comprehensive review on HDL and the risk of CVD. Does functionality matters?
Discussion: 15 mins
11:00-11:30

Break
11:30-12:30 Lecture: Eric Bruckert

CV Risk evaluation through Algorithms

Objective: to discuss different algorithms used for risk evaluation and how to improve their utilisation in clinical practice
Discussion: 15 mins
12:30-13:30

Lecture: Olov Wiklund

Update on new EAS/ESC Joint European Guidelines for the Prevention and Treatment of Dyslipidemia

Discussion: 15 mins

13:30-14:30

Lunch
14:30-15:30 Lecture: Lale Tokgözoglu

Imaging of arteries: does it help to improve risk evaluation? 

Objective: to discuss different imaging strategies including calcium score and ultrasound examination to help identify high risk patients
Discussion: 15 mins
15:30-16:30 Clinical Rounds: All Faculty

Eight groups to prepare short debates (for each topic, one group prepares the Pro and the other group, the Counter arguments) with a short presentation (<5mins) on:

1) Dietary advice in patients with hypercholesterolemia: is it useful?
2) Mixed dyslipidemias involving low HDL-C and/or high Lp(a) ; therapeutic strategies?
3) Dyslipidemic patients with Renal Disease: Is lipid-lowering validated?

Interactive Discussion: what should we do in clinical practice?
16:30-17:00 Break
17:00-18:00 Samir Saheb

Visit of the LDL apheresis center for treatment of severely dyslipidemic patients
18:00 End of the First Day
 

Programme: February 10, 2012

09:00-10:00

Lecture: John Chapman

New Therapeutic Approaches in Lipidology

Objective: To discuss residual risk and what we may expect with future lipid lowering agents (CETP inhibitors, antisense RNA, etc..)
Discussion: 15 mins

10:00-11:00

Lecture: Eric Bruckert and Alain Carrié  

Familial hypercholesterolemia: can we do a better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?

Objective: to improve management of patients with Familial Hypercholesterolemia including children and to discuss the potential impact of genetic screening.
Discussion: 15 mins
11:00-11:30 Break
11:30-12:45

Clinical Rounds: All Faculty

Presentation of clinical cases; interactive discussion with participants

Boris Hansel

Logistics and functioning of clinical unit for patiens with metabolic syndrome

12:45-13:45

Lunch 
14.00-14.45   
Lecture: Borge Nordestgaard
New advances in the role of Lp(a) in atherosclerosis; Therapeutic implications
14:45-15:15 Lecture: Jean-Phillipe Collet

Comprehensive management of dyslipidemic patients at risk: Should we prescribe antiaggregants?
15:15-15:45 Round Table Discussion
15:45-16:00 Closing Remarks and Feedback from Participants
16:00 Meeting Close

Group transport to Airports